FUJIFILM Cellular Dynamics (FCDI) specializes in advanced stem cell technologies, particularly focusing on induced pluripotent stem cells (iPSCs) to develop a range of therapeutic applications. Their product offerings include various cell types such as iCell Cardiomyocytes, iCell Astrocytes, and iCell Hepatocytes, which are utilized in drug discovery, disease modeling, and regenerative medicine. FCDI's expertise extends to creating custom cell development solutions and providing integrated drug discovery services, enabling researchers to explore the molecular mechanisms of diseases and assess drug toxicity more effectively. Their iPSC-derived products are designed to offer biologically relevant human cell models that can replace traditional animal testing, thereby enhancing the predictability of drug responses.

In addition to their cell products, FCDI is also advancing the field of extracellular vesicle (EV) therapeutics, providing a comprehensive solution for the development and manufacture of EV-based therapies. Their EV Total Solution encompasses high-quality reagents, isolation, and characterization services, supporting researchers in their preclinical and clinical development efforts. FCDI's capabilities include cGMP manufacturing, which ensures that their products meet stringent regulatory standards for clinical applications. By leveraging their extensive expertise in stem cell technology and EV therapeutics, FCDI aims to address significant health challenges, including neurodegenerative diseases, heart disease, and cancer, ultimately contributing to improved healthcare outcomes.

United States

Fujifilm Cellular Dynamics, Inc. develops and manufactures biologically relevant human cells derived from induced pluripotent stem (iPS) cells. Our iCell® and donor-specific MyCell® Products are highly pure, highly reproducible, and available in industrial quantity to enable drug discovery, toxicity testing, stem cell banking, and cell therapy development.

FUJIFILM Cellular Dynamics

Company Details